The problem of low levels of vitamin D and osteoporosis: Use of combination therapy with alendronic acid and colecalciferol (vitamin D3)

Drugs and Aging

Volumn 23, Issue 8, 2006, Pages 617-625

  Epstein, Sol ^a,b  

^a Doylestown Hospital   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D;

BONE METABOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FRAGILITY FRACTURE; HEALTH BEHAVIOR; HUMAN; LIFESTYLE; MINERAL METABOLISM; NEUROMUSCULAR FUNCTION; OSTEOCLAST; OSTEOPOROSIS; PATIENT COMPLIANCE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; VITAMIN BLOOD LEVEL; VITAMIN DEFICIENCY; WEIGHT BEARING;

ALENDRONATE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CHOLECALCIFEROL; DRUG COMBINATIONS; HUMANS; OSTEOPOROSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 33748691802     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623080-00001     Document Type: Review

References (103)

1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95
2. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002
3. The burden of brittle bones: costing osteoporosis in Australia. Canberra, Australia: Access Economics Pty Limited, 2001 Sep
4. International Osteoporosis Foundation. Osteoporosis in Europe: indicators of progress. Nyon, Switzerland: International Osteoporosis Foundation, 2005
5. International Osteoporosis Foundation. The facts about osteoporosis and its impact [online]. Available from URL: http://www.osteofound.org/press_centre/ fact_sheet.html [Accessed 2005 Jul 15]
6. Chan KM, Anderson M, Lau EMC. Exercise interventions: defusing the world's osteoporosis time bomb. Bull World Health Organ 2003; 81: 827-30
7. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 Suppl.): S1-S34
8. Compston JE, Papapoulos SE, Blanchard F, on behalf of a Working Party from European Union Member States. Report on osteoporosis in the European community: current status and recommendations for the future. Osteoporos Int 1998; 8: 531-4
9. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7: 407-13
10. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998; 8 Suppl. 4: S1-S88
11. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24-35
12. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004; 15: 897-902
13. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997; 103 (2A): 20S-6S
14. Cummings SR, Melton Jr L. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-7
15. Sambrook PN, Seeman E, Phillips SR, et al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust 2002; 176 Suppl.: S1-S16
16. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 1999; 10: 259-64
17. Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. Clin Ther 1999; 21: 1025-44
18. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Exp Opin Pharmacother 2000; 1: 225-38
19. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100
20. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27: 687-94
21. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37
22. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36: 315-28
23. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12: 1700-7
24. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12: 1-12
25. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-11
26. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
27. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41
28. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82
29. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9 (5): 461-8
30. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22: 15-28
31. Rizzoli R, Greenspan SL, Bone HG, et al. Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17: 1988-96
32. Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004; 34: 890-9
33. Kendler D, Kung AWC, Fuleihan GE-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48: 243-51
34. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24: 1871-86
35. Working Party Writing Group. Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. London: Royal College of Physicians, 2001
36. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. DRI: dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: Institute of Medicine, 1999
37. Bouillon R, Carmeliet G, Daci E, et al. Vitamin D metabolism and action. Osteoporos Int 1998; 8 Suppl. 1: S13-9
38. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257-64
39. Gerdhem P, Ringsberg KAM, Obrant KJ, et al. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA study of elderly women. Osteoporos Int 2005; 16: 1425-31
40. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1003-8
41. RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621-8
42. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr 2004; 80 (6 Suppl.): 1706S-9S
43. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80 (6 Suppl.): 1689S-96S
44. Suda T. Vitamin D and bone: how does vitamin D regulate bone formation and resorption? Proc Jpn Acad 2004; 80 (Ser B): 407-21
45. Goltzman D, Miao D, Panda DK, et al. Effects of calcium and of the vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J Steroid Biochem Mol Biol 2004; 89-90: 485-9
46. Weaver CM, Fleet JC. Vitamin D requirements: current and future. Am J Clin Nutr 2004; 80 (6 Suppl.): 1735S-9S
47. Norman AW. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr 1998; 67: 1108-10
48. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem 2003; 88: 296-307
49. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 1999; 277: F157-75
50. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501
51. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998; 78: 1193-231
52. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-87
53. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status [editorial]. Osteoporos Int 2005; 16: 713-6
54. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7: 439-43
55. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol 2005; 62: 265-81
56. Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 1997; 65: 67-71
57. McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporos Int 1998; 8 Suppl. 1: S3-6
58. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90: 3215-24
59. Carter GD, Carter CR, Gunter E, et al. Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol 2004; 89-90: 467-71
60. Carter GD, Carter R, Jones J, et al. How accurate are assays for 25-hydroxyvitamin D? Data from the International Vitamin D External Quality Assessment Scheme. Clin Chem 2004; 50: 2195-7
61. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004; 89: 3152-7
62. Lips P, Chapuy MC, Dawson-Hughes B, et al. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999; 9: 394-7
63. Glendenning P, Noble JM, Taranto M, et al. Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem 2003; 40: 546-51
64. Glendenning P. Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D. Am J Clin Nutr 2003; 77: 522-3
65. Glendenning P, Fraser WD. 25-OH-vitamin D assays [letter]. J Clin Endocrinol Metab 2005; 90: 3129
66. Raiten DJ, Picciano MF. Vitamin D and health in the 21st century: bone and beyond: executive summary. Am J Clin Nutr 2004; 80 (6 Suppl.): 1673S-7S
67. Welch TR, Bergstrom WH, Tsang RC. Vitamin D-deficient rickets: the reemergence of a once-conquered disease. J Pediatr 2000; 137: 143-5
68. Armas LAG, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-91
69. Heaney RP, Davies KM, Chen TC, et al. Human serum 25- hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-10
70. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-56
71. Vieth R, Chan P-CR, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001; 73: 288-94
72. Venning G. Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ 2005; 330: 524-6
73. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18: 343-51
74. Montero-Odasso M, Duque G. Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. Mol Aspects Med 2005; 26: 203-19
75. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-8
76. Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporos Int 2002; 13: 187-94
77. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged ≥ 60 y. Am J Clin Nutr 2004; 80: 752-8
78. Cheng S, Tylavsky F, Kroger H, et al. Association of low 25-hydroxyvitamin D concentrations with elevated parathyroid hormone concentrations and low cortical bone density in early pubertal and prepubertal Finnish girls. Am J Clin Nutr 2003; 78: 485-92
79. Looker AC, Dawson-Hughes B, Calvo MS, et al. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002; 30: 771-7
80. Gannage-Yared M-H, Chemali R, Yaacoub N, et al. Hypovitaminosis D in a sunny country: relation to lifestyle and bone markers. J Bone Miner Res 2000; 15: 1856-62
81. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the Multiple Outcomes of Raloxifene Evaluation clinical trial. J Clin Endocrinol Metab 2001; 86: 1212-21
82. Levis S, Gomez A, Jimenez C, et al. Vitamin D deficiency and seasonal variation in an adult south Florida population. J Clin Endocrinol Metab 2005; 90: 1557-62
83. van der Wielen RPJ, Lowik MRH, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995; 346: 207-10
84. Chapuy MC, Schott AM, Garnero P, et al. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Metab 1996; 81: 1129-33
85. Bhattoa HP, Bettembuk P, Ganacharya S, et al. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in community dwelling postmenopausal Hungarian women. Osteoporos Int 2004; 15: 447-51
86. Harinarayan CV. Prevalence of vitamin D insufficiency in postmenopausal south Indian women. Osteoporos Int 2005; 16: 397-402
87. Isaia G, Giorgino R, Rini GB, et al. Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos Int 2003; 14: 577-82
88. Thiebaud D, Burckhardt P, Costanza M, et al. Importance of albumin, 25 (OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture. Osteoporos Int 1997; 7: 457-62
89. LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999; 281 (16): 1501-11
90. Bruce DG, St John A, Nicklason F, et al. Secondary hyperparathyroidism in patients from Western Australia with hip fracture: relationship to type of hip fracture, renal function, and vitamin D deficiency. J Am Geriatr Soc 1999; 47: 354-9
91. Pfeifer M, Minne HW. Vitamin D and hip fracture. Trends Endocrinol Metab 1999; 10: 417-20
92. Gallacher SJ, McQuillan C, Harkness M, et al. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. Curr Med Res Opin 2005; 21: 1355-61
93. Simonelli C, Weiss TW, Morancey J, et al. Prevalence of vitamin D inadequacy in a minimal trauma fracture population. Curr Med Res Opin 2005; 21: 1069-74
94. Gaugris S, Heaney RP, Boonen S, et al. Vitamin D inadequacy among post-menopausal women: a systematic review. Q J Med 2005; 98: 667-76
95. National Institutes of Health. NIH Consensus Development Conference on Osteoporosis Prevention, Diagnosis, and Therapy. Bethesda (MD): National Institutes of Health, 2000
96. Boonen S, Body JJ, Boutsen Y, et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2005; 16: 239-54
97. Lips P, Shimizu H, Chandler J, et al. Global prevalence of vitamin D inadequacy among community dwelling women with osteoporosis [abstract]. Bone 2005; 36 Suppl. 2: S460
98. FOSAMAX PLUS D prescribing information [online]. Available from URL: www.fosamax.com/alendronate_sodium/fosamax/hcp/fosamax_plus_d [Accessed 2005 Aug 26]
99. Lips PT, Recker RR, Rosen CJ, et al. The effect of a once-weekly tablet containing alendronate and vitamin D3 for the treatment of osteoporosis. Curr Med Res Opin 2006; 22: 1745-55
100. Resch H, Wehren LE, Sen SS. Vitamin D in osteoporosis: attitudes and beliefs of patients and physicians [abstract no. P319]. Osteoporos Int 2006; 17 Suppl. 1: S89
101. Antoniucci DM, Vittinghoff E, Blackwell T, et al. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 2005; 90: 4566-72
102. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97
103. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004; 21: 793-811